James Januzzi, MD

Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD

The shift from purely clinical heart failure diagnosis to biomarker-guided management unfolded over decades of incremental evidence, institutional skepticism, and a handful of pivotal decisions by a small number of physician-scientists willing to champion tools before their adoption became mainstream.

 host Alexander Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, interviews Jim Januzzi, MD, the Adolph Hutter Professor of Medicine at Harvard Medical School, chief scientific officer and Gibson chair at the Baim Institute for Clinical Research, and a cardiologist at Massachusetts General Hospital, to explore the formative experiences, clinical innovations, and leadership principles that shaped his career and, more broadly, the evolution of modern cardiology.

Januzzi described nearly declining the opportunity to conduct the first US-based clinical studies with NT-proBNP in 2002, having positioned himself primarily as a troponin and acute coronary syndrome researcher. The foundational diagnostic and prognostic work he ultimately led at MGH established the NT-proBNP cutoffs now used internationally, and the test has since evolved from an emergency department dyspnea evaluation tool into a biomarker used across all phases of heart failure management. He noted sacubitril/valsartan as a particularly meaningful convergence of therapeutic and biomarker science, consistently producing substantial reductions in NT-proBNP regardless of baseline value, a finding he has incorporated as a practical signal of adequate neurohormonal blockade.

On the broader arc of guideline-directed medical therapy (GDMT), Januzzi reflected on witnessing the introduction of beta-blockers for heart failure as a fellow, a shift once considered counterintuitive, and tracing the subsequent addition of each pillar as a reminder that even well-established treatment paradigms remain open to displacement by rigorous evidence. He described his involvement in the endpoint committee for the EMPA-REG OUTCOME trial as the entry point for his work with SGLT2 inhibitors in heart failure, another opportunity initially approached with ambivalence. Despite four-pillar GDMT, he noted residual event rates underscore the continued need for novel therapeutics, and he expressed enthusiasm for gene-editing approaches and RNA-silencing therapies now entering cardiovascular development pipelines.

Across the conversation, Januzzi returned to the role of mentorship and deliberate career planning, including maintaining clinical trial involvement from early protocol design rather than joining established programs at the phase three stage, advocating for sponsorship alongside mentorship, and structuring academic evolution in intentional five-year increments. The discussion positions biomarker-guided heart failure care not as a completed project but as a framework still being refined as the disease's diagnostic boundaries and therapeutic options continue to expand.

Podcasts

Hear Jim Januzzi, MD, discuss how he overcame academic shortcomings to become one of the preeminent voices in cardiology biomarkers.

Making Heart Failure Prevention Accessible

A joint statement by the American Society for Preventive Cardiology (ASPC) and the Heart Failure Society of America (HFSA), published on August 13, 2025, shifts the focus of 

 from recovery to prevention for the first time. “The Continuum of Prevention and Heart Failure in Cardiovascular Medicine” provides clinicians with a framework of strategies to apply across all stages of heart failure, irrespective of ejection fraction.

Instead of viewing the condition as an inevitable outcome, this statement recontextualizes heart failure as a preventable condition. It encourages clinicians to identify and manage risk factors earlier through methods such as glucose management, genetic risk screening, lifestyle interventions, weight loss, and blood pressure control.

In the seventh and final episode of a 7-part 

, moderator James Januzzi, MD, is joined by Martha Gulati, MD, MS, and Anu Lala, MD, to discuss the urgent need to bridge the gap between prevention and heart failure care.

Januzzi highlights ongoing inequities in cardiovascular care, noting that heart failure and related risk factors disproportionately affect marginalized populations with limited access to quality healthcare. He stresses that addressing these disparities will require significant health system and policy changes, especially as demographic shifts in the U.S. are projected to increase the burden of disease in these communities.

Lala adds 5 key takeaways for primary care: heart failure is preventable; prevention applies across the lifespan; screening should start early using tools like natriuretic peptides and UACR; patient care must take a whole-person, whole-team approach; and clinicians should proactively prescribe effective therapies such as SGLT2 inhibitors, ARNIs, and aggressive blood pressure control.

, is the Hutter Family Professor of Medicine at Harvard and the Director of Heart Failure and Biomarker Trials at the Balm Institute for Clinical Research. Januzzi serves as the moderator for this conversation.

, is the associate director of the Barbra Streisand Women Heart Center and the director of CVD Prevention at the Smidt Heart Institute at Cedars Sinai Medical Center. She was also the president of the ASPC from 2022-2024.

, is an associate professor of medicine at the Zena & Michael A Wiener Cardiovascular Institute, and a member of the Department of Population Health Science and Statistics at Icahn School of Mount Sinai and Mount Sinai Hospital.

Editors’ Note: Januzzi reports disclosures with Abbott Laboratories, AbbVie, Inc., Eli Lilly, AstraZeneca Pharmaceuticals, Jana Care, Siemens, and others. Gulati reports disclosures with the American Society of Preventive Cardiology, Eli Lilly, Merck & Co., Boehringer Ingelheim Pharmaceuticals, Medtronic, Zoll, and others. Lala reports disclosures with Abiomed, AstraZeneca, Merck & Co., Novo Nordisk, Sequana, Bayer, and others.

Heart Failure Society of America. Heart Failure Society of America and American Society for Preventive Cardiology Joint Statement Calls for a Shift in Heart Failure Prevention and Care. 

 August 13, 2025. Accessed September 9, 2025. 

https://www.prnewswire.com/news-releases/heart-failure-society-of-america-and-american-society-for-preventive-cardiology-joint-statement-calls-for-a-shift-in-heart-failure-prevention-and-care-302529062.html

Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in Cardiovascular Medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. American Journal of Preventive Cardiology. Published online August 13, 2025:101069. 

Videos

In the final segment of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

HFSA/ASPC Heart Failure Prevention: Making Heart Failure Prevention Accessible

Heart Failure in Women

Instead of viewing the condition as an inevitable outcome, this statement recontextualizes heart failure as a preventable condition. It encourages clinicians to identify and manage risk factors earlier through methods such as glucose management, genetic risk screening, lifestyle interventions, weight loss, and blood pressure control.1

 moderator James Januzzi, MD, is joined by Martha Gulati, MD, MS, and Anu Lala, MD, to discuss the urgent need to bridge the gap between prevention and heart failure care.

Lala outlines three key priorities for improving prevention in women at risk for heart failure: early identification, closing implementation gaps, and driving policy and payment reform. She stresses that many existing risk tools are based on male populations, which leads to underrecognition of women’s risks. Since women more commonly present with heart failure with preserved ejection fraction (HFpEF) rather than systolic dysfunction, prevention strategies must reflect these differences. She also emphasizes that women often receive less therapy and attention than men, making equitable implementation critical to improving outcomes.

Gulati expands on this, highlighting the importance of sex-specific risk factors in refining risk assessment. Traditional risk calculators, heavily weighted by age, often underestimate the risks faced by young women, such as those experiencing adverse pregnancy outcomes like preeclampsia, gestational diabetes, or hypertension during pregnancy. 

These conditions elevate risks for both cardiovascular disease and heart failure within a decade, not just later in life. She also draws attention to peripartum cardiomyopathy and Takotsubo syndrome—forms of heart failure disproportionately affecting women—that are often underdiagnosed and lack effective preventive strategies.

Both experts agree that greater inclusion of women in clinical trials is essential for understanding how therapies apply across sexes. Gulati notes that intentional enrollment efforts have already begun to improve representation in heart failure research, shifting from historically poor female participation toward more balanced studies. This progress, she argues, demonstrates that with deliberate action, clinical trials can better capture sex differences, ultimately informing more effective and equitable care for women at risk of or living with heart failure.

In part 6 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

HFSA/ASPC Heart Failure Prevention: Heart Failure in Women

Addressing Unmet Needs in Heart Failure

Gulati identifies several pressing unmet needs in heart failure prevention, beginning with chronic kidney disease. She stresses that reliance on GFR alone is inadequate, as kidney damage is already present when GFR changes, and advocates for broader use of the urine albumin-to-creatinine ratio (UACR) as an essential biomarker.

She also highlights major gaps in basic risk factor management, particularly hypertension control, noting that only a small fraction of patients are adequately treated despite hypertension being highly modifiable. Gulati emphasizes the need for structured approaches—such as checklists, electronic health record prompts, and system-level interventions—to ensure guideline-directed therapy is consistently applied.

Januzzi reinforces the value of systematic programs, describing how at Mass General, nurse practitioners, physician assistants, and pharmacists are central to a guideline-directed medical therapy program that has dramatically improved outcomes for heart failure patients. He argues that similar team-based models should be extended to earlier stages of disease, not just advanced cases. This approach, he says, helps reverse dysfunction, improve quality of life, and ultimately reduce costs.

In part 5 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

James Januzzi, MD

Articles